top of page
Photo of April K.S. Salama, M.D.

Medical Oncologist

April K.S. Salama, M.D.

As a physician-scientist and specialist in melanoma that has metastasized (spread) to other parts of the body, I care for patients with this cancer in the clinic and search for new therapies to control and cure the disease. Since joining Memorial Sloan Kettering in 1988, I have diagnosed and treated thousands of patients with metastatic melanoma. This aggressive type of cancer begins in specialized pigment cells and spreads from its original site to lymph nodes, and eventually to other parts of the body. In the past decade, we have gained significant insights into two areas of melanoma that have led to drug development. The first finding relates to genetic errors contained inside a melanoma cell, and has enabled the development of drugs that target these errors. The second is an expanded understanding of how the body’s immune system can recognize cancers like melanoma. From this we have learned how to activate a vigorous immune response against the disease. In an advance that helped to launch a new era of personalized medicine in melanoma treatment, I led a clinical trial that partially paved the way for the 2011 approval of vemurafenib (Zelboraf®), by the US Food and Drug Administration. This drug targets a mutation in a gene called BRAF, which is present in about half of patients who have metastatic melanoma. We also learned that a small proportion of melanomas have mutations in other genes, some of which we can target with different drugs. In addition, I was one of five Memorial Sloan Kettering scientists recently appointed to a melanoma “Dream Team” sponsored by the nonprofit organization Stand Up To Cancer and the Melanoma Research Alliance. This team’s project focuses on identifying potential therapies for metastatic melanoma patients who do not have the mutated form of the BRAF gene. My collaboration with Memorial Sloan Kettering colleagues led to the 2011 FDA approval of the monoclonal antibody ipilimumab (Yervoy™), which prompts the body’s immune system to recognize cancers like melanoma as foreign. I also am working to develop vaccines against melanoma that we hope can be used to direct the patient’s immune system against melanoma cells that may remain following successful treatment. In addition to my work at Memorial Sloan Kettering, I am a professor of medicine at the Weill Cornell Medical College and am active in a number of scientific organizations such as the American Association for Cancer Research, the Society for Melanoma Research, and the American Society of Clinical Oncology. I also serve as the chair of the Melanoma Research Alliance Medical Advisory Panel. I am proud to have received a number of honors and awards for my clinical research, such as the Wings of Hope Award in 2007 from the Melanoma Research Foundation.

More Experts


Dr. Dan 



Richard D_edited_edited.jpg

Dr. Richard Carvajal

Medical Oncology

peter chen_edited_edited.jpg

Dr. Peter Chen

Radiation Oncologist

Interview with April K.S. Salama





(0:04 - 1:18)




(1:24 - 4:27)

What is the NCCN? The process in making the NCCN Melanoma Guideline



(4:28 - 6:12)

Listen to Dr. Salama’s philosophy in consulting her melanoma patients.



(6:12 - 9:14)

How to decide the type of treatment for patients with Stage IV Melanoma, specifically targeted therapy vs. Immunotherpay



(9:15 - 17:01)

Decision making process to use immunotherapy for Stage IV melanoma, specifically on single agent vs. dual agents



(17:02 - 21:25)

How to monitor and avoid adverse side effects associated with immunotherapy



(21:41 - 22:14)

What to do when immunotherapy does not work for patients with stage IV



(22:15 - 26:05)

Adjuvant treatment for patients with Stage III melanoma



(26:06 - 30:26)

Neo-adjuvant treatment for patients with stage III melanoma



(30:27 - 32:09)

Adjuvant treatment for patients with stage II melanoma



(32:10 - 34:57)

Dispelling misconceptions on Clinical trials for melanoma treatment



(35:02 - 36:21)

Advice for patients with advanced staged disease

bottom of page